We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Simple Blood Test for Esophageal Cancer Could Reduce Invasive Endoscopy Procedures

By LabMedica International staff writers
Posted on 22 Jun 2022
Print article
Image: New test could detect protein ‘fingerprints’ in the blood (Photo courtesy of Pexels)
Image: New test could detect protein ‘fingerprints’ in the blood (Photo courtesy of Pexels)

Barrett’s esophagus is a pre-malignant condition that occurs when the esophagus is damaged by acid reflux. Barrett’s esophagus is asymptomatic and associated with an increased risk of esophageal cancer. Esophageal cancer is an area of significant unmet medical need, with current screening requiring specialist medical expertise. Now, a simple blood test targeted at patients with Barrett’s esophagus could detect biomarkers for esophageal adenocarcinoma that were already validated in a 300 patient study earlier this year.

Proteomics International (Perth, Australia) has secured an exclusive worldwide license to commercialize biomarkers that can test for esophageal adenocarcinoma, the most common form of esophageal cancer. The license agreement between Proteomics and the QIMR Berghofer Medical Research Institute (Queensland, Australia) was signed following a partnership between the two organizations to improve detection of the disease.

The QIMR Berghofer intellectual property in the biomarkers is licensed exclusively to Proteomics and will allow the company to use the biomarkers discovered by QIMR Berghofer researchers to develop and commercialize a simple blood test for esophageal adenocarcinoma. The license agreement comes after Proteomics and QIMR Berghofer validated the biomarkers in a joint study of more than 300 patients earlier this year. Proteomics will now undertake additional studies to confirm the diagnostic performance of the potential new blood test, which will take approximately six months and would be targeted at patients with Barrett’s esophagus.

“These at-risk patients are currently screened with invasive and costly endoscopy procedures. Instead, this panel of biomarkers - or protein ‘fingerprints’ in the blood - can detect the early stages of esophageal adenocarcinoma which we hope to do using a simple blood test,” said Dr. Richard Lipscombe, managing director of Proteomics International.

Related Links:
QIMR Berghofer 
Proteomics International 

Gold Supplier
POC Test Reader
STI Test Kit
PlexPCR HSV-1&2, VZV
POC Pathogen Detection & Gene Expression System
Sal6830 Mobile Workstation
1,5-AG Test
1,5-Anhydroglucitol Test Kit

Print article
IIR Middle East



view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more


view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.